MHR: Inflammation Divided by Vascular Protection
Monocyte-to-HDL Ratio (MHR) blood testing calculates the proportion of monocytes to high-density lipoprotein in circulation. Monocytes (innate immune white blood cells) are made in the bone marrow and travel in the bloodstream before moving into tissues, where they can mature into macrophages. HDL (high-density lipoprotein, often called "good cholesterol") consists of small, protein-rich particles produced mainly by the liver and intestine that ferry cholesterol through the blood.
MHR distills two biologic forces into one number: the body's inflammatory drive versus its vascular protection. Monocytes can amplify inflammation and, after entering vessel walls, contribute to plaque development by becoming lipid-laden foam cells. HDL counters this by removing cholesterol from tissues (reverse cholesterol transport) and by exerting anti-inflammatory and antioxidant effects on the endothelium. As a result, MHR reflects the balance between pro-inflammatory cellular activity and protective lipid transport—an integrated snapshot of immune–lipid interplay relevant to vascular health. Because it combines common elements of a blood count and lipid profile, MHR offers a concise view of the milieu that favors or restrains atherosclerosis (arterial plaque formation).
Why a Two-Cell Ratio Captures Cardiometabolic Stress
The monocyte-to-HDL ratio (MHR) captures the tug-of-war between inflammatory white blood cells and the anti-inflammatory, endothelial-protective actions of HDL cholesterol. A higher ratio points to more immune activation relative to vascular cleanup and repair, flagging vessel wall stress, plaque activity, and broader cardiometabolic inflammation.
The MHR combines two counterbalancing signals: circulating monocytes (innate immune activity) divided by HDL cholesterol (anti-inflammatory and antioxidant capacity). It is a compact gauge of inflammatory load versus lipid "buffering," relevant to vessel health, metabolic efficiency, cardiac risk, cognitive resilience, and overall recovery capacity.
Interpreting a Low, Mid, or High MHR
There is no single reference range; labs compute MHR differently. In healthy adults it tends to sit mid-range, and lower within that band is generally more favorable. A low ratio from strong HDL with normal monocytes signals quiet inflammation and healthier endothelium, usually without symptoms. If very low because monocytes are below normal, it may indicate reduced innate immunity, with recurrent infections or slow wound healing.
Low values usually reflect fewer circulating monocytes and/or higher HDL. This points to a quieter innate immune tone with robust reverse cholesterol transport and oxidative stress control. In some cases, very low values can occur with reduced bone marrow output, recent glucocorticoid exposure, or immune suppression; in older adults this may parallel increased infection susceptibility. Premenopausal women often show lower MHR given typically higher HDL.
Being in range suggests balanced immune surveillance with adequate HDL-mediated cholesterol efflux, supporting endothelial stability, flexible vascular reactivity, and steadier metabolic signaling. Observational data generally associate the low-to-mid portion of the reference range with favorable cardiometabolic profiles.
A high ratio—via more monocytes and/or low HDL—indicates a pro-inflammatory, pro-atherogenic milieu. It aligns with endothelial dysfunction, plaque activity, insulin resistance, fatty liver, and kidney microvascular stress. Often silent, it can coexist with fatigue or metabolic-syndrome features. Men generally run higher ratios than premenopausal women; after menopause values converge. In pregnancy, both HDL and monocytes shift, so pregnancy-specific interpretation matters. In children and teens, developmental changes in immunity and lipids make context essential.
High values usually reflect heightened monocyte-driven inflammation and/or low HDL, signaling reduced anti-inflammatory buffering. This milieu favors endothelial dysfunction, plaque formation, pro-thrombotic tendency, insulin resistance, fatty liver progression, and microvascular kidney stress. MHR often rises with acute infections and chronic inflammatory or cardiometabolic states; it tends to be higher with aging and after menopause as HDL declines.
What Can Shift an MHR Reading
Interpretation is influenced by acute illness, recent strenuous exercise, smoking, and circadian timing. HDL is measured enzymatically and is minimally affected by fasting, while monocyte counts come from the CBC and vary with stress hormones. Medications that alter leukocytes or HDL (e.g., corticosteroids, immunosuppressants, estrogens, lipid-lowering agents) can shift MHR.
What MHR Adds to a Standard Cardio Workup
Big picture, MHR links immune tone with lipid transport and vascular repair. It complements CRP, neutrophil-to-lymphocyte ratio, LDL, triglycerides, HbA1c, and kidney measures, and higher values have been associated with greater long-term cardiometabolic and atherosclerotic risk, while lower values suggest a more resilient vascular state.
FAQs
MHR is calculated from two routine labs: absolute monocyte count (from a CBC with differential) and HDL cholesterol (from a lipid panel). It reflects the balance between inflammatory white blood cell activity and HDL’s protective capacity.
Testing MHR adds context to standard CBC and lipid results, helping identify when immune activity is high relative to HDL protection and supporting earlier, more personalized risk assessment.
Test at intervals that let you detect trends rather than single-day noise. Many people retest periodically (for example, quarterly) or during periods of lifestyle or therapy change. Keep collection conditions consistent.
Smoking, sleep, visceral fat, fitness status, acute infections, recent strenuous exercise, and glucocorticoids can shift monocytes, HDL, or both, influencing the ratio.
No special preparation is required beyond what’s typical for a CBC and lipid panel. Consistent timing, activity, and meal patterns improve comparisons over time.
Superpower currently offers at-home blood testing in the following states: Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Idaho, Illinois, Indiana, Kansas, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, and Wisconsin.
We’re actively expanding nationwide, with new states being added regularly. If your state isn’t listed yet, stay tuned.
References
- Ganjali, S., Gotto, A. M., Jr., Ruscica, M., Atkin, S. L., Butler, A. E., Banach, M., & Sahebkar, A. (2018). Monocyte-to-HDL-cholesterol ratio as a prognostic marker in cardiovascular diseases. Journal of Cellular Physiology, 233(12), 9237-9246. https://doi.org/10.1002/jcp.27028
- Guo, Z. G., Li, C., Zhong, J. K., Tu, Y., & Xie, D. (2012). Laboratory investigation of dysfunctional HDL. Chemistry and Physics of Lipids, 165(1), 32-37. https://doi.org/10.1016/j.chemphyslip.2011.10.005
- Feingold, K. R. (2024). Introduction to lipids and lipoproteins. In Endotext. MDText.com, Inc. https://www.ncbi.nlm.nih.gov/books/NBK305896/
- Sniderman, A. D., Williams, K., Contois, J. H., Monroe, H. M., McQueen, M. J., de Graaf, J., & Furberg, C. D. (2011). A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circulation: Cardiovascular Quality and Outcomes, 4(3), 337-345. https://doi.org/10.1161/CIRCOUTCOMES.110.959247
- Nordestgaard, B. G. (2016). Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: New insights from epidemiology, genetics, and biology. Circulation Research, 118(4), 547-563. https://doi.org/10.1161/CIRCRESAHA.115.306249






































.avif)
